Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
February 3, 2016
- Seikagaku, Kaken Call Off Artz Development for Expanded Indication
February 3, 2016
- Sakigake-Designated NS-065 Now in PI/II: Nippon Shinyaku
February 3, 2016
- Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
February 3, 2016
- J-TEC Files Skin-Derived Cell Sheet JACE for Giant Pigmented Nevus
February 2, 2016
- Pola Pharma to Take Over GSK’s Marketing Authorization for Acne Drug Duac
February 2, 2016
- Eisai Gets Japan, Asia Rights to HDAC Inhibitor
February 2, 2016
- Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President
February 2, 2016
- Astellas, Tohoku Univ. Spinoff Link Up on Gene Therapy for Retinitis Pigmentosa
February 2, 2016
- Sanofi Files Japan NDA for Plerixafor in Response to Govt Request
February 2, 2016
- Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
February 2, 2016
- Daiichi Sankyo to Continue Negotiations with FDA on Edoxaban Restriction: CEO
February 1, 2016
- Kyowa Kirin Enjoys 87% Profit Jump in 2015
February 1, 2016
- Kyowa Kirin to Forge Stand-Alone Sales Regime in US: 5 Year Plan
February 1, 2016
- Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
- FDA OKs Eisai’s Halaven for Liposarcoma
February 1, 2016
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
January 29, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…